Recent experience includes:
Advised Apposite Capital, a healthcare investor, on its investment in medical device company, Emblation. Established in 2007, Emblation designs, manufactures and commercialises next generation microwave-based solutions for a range of skin conditions. Its products, which are currently sold in the UK, North America and Australia, have been used in more than 130,000 treatments. This investment will support Emblation's international growth, as well as enable it to expand its technology platform.
Private equity investor and an inventor
Advised a private equity investor and an inventor in relation to a diagnostic and treatment device in the ENT area. We provided strategic and practical legal advice to clarify the position on ownership and control over the product, and to prepare the ground for financial investment into and commercialisation of the device.
Advised private equity firm capiton on a general partner-led single asset secondary transaction relating to the KD Pharma Group.
Woodford Patient Capital Trust plc
Advised on the set up and launch of Woodford Patient Capital Trust plc, an innovative investment trust offering exposure to early-stage companies with outstanding intellectual property and long-term return opportunities.
Advised e-therapeutics plc on fundraise of up to £12.4 million.
French fund manager
Advised on structuring and establishing a life sciences venture fund.
Advised Optum, as the lead investor, investing by way of subscription for Series A Shares, in Oxford VR Limited, resulting in Optum holding 20% of the fully diluted share capital in Oxford VR. Oxford VR is technology company which has developed immersive virtual reality software aimed at treating mental health issues such as anxiety.
Acacia Pharma Group plc
Advised Euronext Brussels-listed Acacia Pharma Group plc on its successful €25 million fundraising through the placing of 12.5 million new ordinary shares at €2 per share with institutional investors in Europe and the US.
Advised UCB on various strategic investments alongside financial investors in various early stage portfolio companies, in both the US and throughout Europe. These included an early stage spin-out from a UK university involved in pioneering cell therapy technology, a Switzerland-based company developing a RNA-targeting drug development platform, a Spanish company developing a neurological chronic pain medical device and a US company developing a novel gene therapy platform for second generation delivery vectors.